In conclusion, we confirmed higher resistin expression in AA women and discovered that resistin is associated with ER-, PR-, HER2-negative and triple negative subtypes, which are more aggressive breast cancer subtypes with limited treatment options. This evidence concerns the gene ESR1 and breast carcinoma.